C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) C07H 21/04 (2006.01) C07K 1/00 (2006.01) C12P 19/34 (2006.01)
Patent
CA 2525029
The present invention is based on the finding that plasma cell disorders such as Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance are characterized by an increase in the expression of JAG2. Accordingly, the present invention provides a method for diagnosis of plasma cell disorders by detecting the expression or overexpression of JAG2. The expression or overexpression of JAG2 may be detected as increased mRNA transcripts or increased protein.
L'invention concerne la découverte selon laquelle des troubles de cellules plasmiques, notamment le myélome multiple et une gammopathie monoclonale de gravité inconnue sont caractérisés par l'augmentation de l'expression de JAG2. Par conséquent, l'invention concerne une méthode de diagnostic de troubles de cellules plasmiques, consistant à détecter l'expression ou la surexpression de JAG2. L'expression ou la surexpression de JAG2 peut être détectée sous la forme d'une augmentation de transcripts d'ARNm d'une augmentation de protéines.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Health Research Inc.
LandOfFree
Use of jag2 expression in diagnosis of plasma cell disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of jag2 expression in diagnosis of plasma cell disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of jag2 expression in diagnosis of plasma cell disorders will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1634447